ArticleFrontiers in pharmacology2023
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Post-marketing safety profile of palivizumab: a 20-year pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Drug-Induced Noninfectious Myocarditis/Pericarditis: A Real-World Pharmacovigilance Study Using the FAERS Database.Cardiovascular toxicology · 2026Article
- Management of toxicities from antibody - drug conjugates in breast cancer.Frontiers in oncology · 2026Review
- Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.Frontiers in pharmacology · 2026Article
- Article
- Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.Frontiers in immunology · 2026Review
- State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.Korean journal of radiology · 2025Review
- Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database.Orphanet journal of rare diseases · 2025Article
- Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer.Therapeutic advances in medical oncology · 2025Review
- Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence.Frontiers in pharmacology · 2025Review
- Article
- Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study.Frontiers in immunology · 2025Article
- Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.Frontiers in pharmacology · 2024Article
- Trop2-targeted therapies in solid tumors: advances and future directions.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.